文献速递真菌感染新发突发、热带与寄生虫病

侵袭性念珠菌感染的免疫治疗:宿主导向策略的临床转化

Immunotherapy for invasive Candida infections: translating host-directed strategies into clinical practice.
PubMed 文献 · Clin Microbiol Infect · 2026-09-07

本文综述了侵袭性念珠菌感染的免疫治疗策略,包括细胞因子、免疫检查点抑制剂、细胞治疗及疫苗和单克隆抗体等。这些策略旨在恢复宿主抗真菌免疫,部分在特定人群显示初步临床获益,但多数仍处于临床前阶段。成功转化需生物标志物驱动的患者分层和严格安全性评估。

要点

  • 免疫治疗作为抗真菌治疗的辅助手段,旨在逆转免疫麻痹。
  • 细胞因子和检查点抑制剂有初步证据,细胞治疗多处于临床前。
  • 临床转化需生物标志物分层和机制驱动的适应性试验设计。

核心结论

  • 免疫治疗有望通过宿主导向干预补充抗真菌治疗,改变侵袭性念珠菌病的管理。

研究设计与样本

  • 综述,通过聚焦检索PubMed/MEDLINE、Embase和ClinicalTrials.gov,并补充作者个人收藏和参考文献筛选。

主要发现

  • 细胞因子(如干扰素-γ和粒细胞/巨噬细胞集落刺激因子)在特定人群显示初步临床获益。
  • 免疫检查点抑制剂有临床前数据支持,但IFD临床证据有限。
  • 细胞治疗(粒细胞输注、过继T细胞转移、CAR-T和CAR-NK)大多仍处于临床前。
  • 疫苗和单克隆抗体在临床前和早期临床研究中显示有希望的免疫原性和抗真菌活性。

临床怎么用

  • 免疫治疗可作为传统抗真菌治疗的辅助,但需根据患者免疫状态通过生物标志物进行分层。
  • 临床应用前需严格评估安全性,尤其考虑患者免疫状态的异质性。

局限性

  • 多数免疫治疗策略的临床证据有限,尤其检查点抑制剂和细胞治疗。
  • 需要实时生物标志物驱动的患者分层和严格安全性评估。
  • 未来研究应优先采用适应性、机制为基础的试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Candida infections are a leading cause of invasive fungal disease (IFD), especially among critically ill and immunocompromised patients. Despite available pathogen-directed antifungal therapies, outcomes remain unsatisfactory with high associated morbidity and mortality rates. Increasing recognition of immune dysregulation of the host, including immunoparalysis and impaired antifungal effector responses, has driven interest in immunotherapeutic strategies as adjuncts to conventional treatment. OBJECTIVES: To provide a comprehensive overview of emerging immunotherapeutic approaches for invasive Candida infections and evaluate their mechanistic rationale, current evidence, and potential for clinical translation. SOURCES: Relevant literature was identified through a focused search of PubMed/MEDLINE, Embase, and ClinicalTrials.gov, supplemented by the authors' personal collection of key studies and reference screening. CONTENT: Immunotherapeutic strategies targeting invasive Candida infections encompass both noncellular and cellular approaches. Cytokine-based therapies, including interferon-γ and granulocyte/macrophage colony-stimulating factors, aim to restore impaired innate immunity and have demonstrated preliminary clinical benefits in selected populations. Immune checkpoint inhibitors represent a novel strategy to reverse T-cell exhaustion, supported by preclinical data but with limited clinical evidence to date in IFD. Cellular therapies, such as granulocyte transfusions, adoptive T-cell transfer, and engineered chimeric antigen receptor T and chimeric antigen receptor natural killer cells, offer innovative means to augment antifungal immunity, although their use remains largely preclinical. Preventive and therapeutic strategies involving vaccines and monoclonal antibodies are advancing, with several candidates showing promising immunogenicity and antifungal activity in preclinical and early clinical studies. IMPLICATIONS: Immunotherapy has the potential to transform the management of invasive candidiasis by complementing antifungal therapy with host-directed interventions. Successful clinical translation will require real-time biomarker-driven patient stratification and rigorous safety evaluations to account for the heterogeneity of patients according to their immune status. Future research should prioritize adaptive, mechanism-based trial designs to enable precision immunotherapy and improve outcomes in high-risk populations.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Sprute R, Singh S, Conti HR, et al. Immunotherapy for invasive Candida infections: translating host-directed strategies into clinical practice. Clin Microbiol Infect. 2026. PMID: 42705534. doi:10.1016/j.cmi.2026.08.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。